01 Expansion of Antibody–Drug Conjugates and Other Bioconjugates The biologics market analysis indicates that advances in linker chemistry, payload design, and antibody engineering are expanding antibody–drug conjugates (ADCs) as a way to deliver potent therapies more selectively to target cells; 13 ADCs had received FDA approval by June 2025, targeting 11 different antigens with seven distinct cytotoxic payloads.
02 Development of Long-Acting Biologic Formulations Demand for less frequent dosing and improved treatment convenience is also driving the development of long-acting biologic formulations, with half-life extension and Fc engineering helping maintain therapeutic exposure for longer periods; in 2025, the FDA approved two half-life-extended antibody products among its new antibody-based biologics.
01 Demand for Personalized Biologic Therapies and Investment in Biologic Drug Development Drive Market The increasing demand for personalized biologic therapies is expanding the need for biologics tailored to specific patient and disease characteristics. Greater use of biomarker testing and patient stratification supports treatment selection based on individual biological profiles, increasing demand for specialized therapies. For example, biomarker testing can help identify cancer patients who may benefit from a specific monoclonal antibody therapy. Higher demand for targeted treatment options encourages pharmaceutical companies to expand biologic development and manufacturing capabilities. This shift toward individualized care therefore supports growth in the biologics market.The rising investment in biologic drug development is expanding the supply pipeline by supporting research, clinical trials, and manufacturing capabilities for new biologic therapies. Higher funding from pharmaceutical companies and biotechnology firms increases the number of biologic candidates progressing through development and commercialization. For example, companies invest in monoclonal antibodies and recombinant proteins for oncology, autoimmune diseases, and other therapeutic areas. A broader development pipeline increases future availability of biologic products and strengthens production capacity. Continued investment therefore supports expansion of the biologics market.
01 Limited Access to Advanced Manufacturing Infrastructure and Complex Manufacturing and Production Processes Restrain Market Expansion Limited access to specialized bioreactors, sterile processing systems, and advanced quality-control facilities can restrict biologics production capacity. High infrastructure costs and technical requirements can make facility development difficult, particularly for smaller manufacturers and emerging markets. These constraints can delay production scale-up and limit broader market expansion.Biologics require controlled production conditions, multiple processing stages, and strict quality checks to maintain product consistency and safety. Process complexity can increase manufacturing time, operational costs, and the risk of batch variability or production failure. These challenges can limit scalability and slow the adoption of biologic therapies.
01 Biologics for Veterinary Therapeutics and Development of Oral and Alternative-Route Biologics Offer Growth Opportunities Veterinary pharmaceutical companies, animal-health providers, and biologics developers can target biologic therapies for companion animals and livestock. Companies such as Zoetis can expand revenue through specialized biologic products for animal diseases, creating an additional market beyond human therapeutics.Biopharmaceutical companies and drug-delivery technology providers can develop oral, inhaled, nasal, and other non-injectable biologic formats. Companies such as Oramed Pharmaceuticals are developing oral delivery technologies, creating opportunities for licensing, formulation partnerships, and new product commercialization.
01 Supply Disruptions for Critical Biologic Inputs and Cold-Chain and Storage Requirements Hinder Growth Dependence on specialized cell-culture media, resins, filters, single-use components, and other inputs can expose manufacturers to supply interruptions. Shortages of single-use bioprocessing components have previously affected biopharmaceutical manufacturers, highlighting how supplier disruptions can delay production and limit reliable product availability.Biologics often require controlled temperature conditions throughout manufacturing, transportation, and storage, increasing logistics complexity and limiting distribution in regions with unreliable cold-chain infrastructure. For example, temperature excursions during vaccine transportation can compromise product quality, leading to product losses and restricting access in markets with weak cold-chain networks.
April 2026 Samsung Biologics expanded its global biologics manufacturing network by commissioning additional large-scale biomanufacturing capacity to support commercial production of monoclonal antibodies and other biologic therapies.
February 2026 Lonza Group launched expanded biologics development and manufacturing services with enhanced mammalian cell culture capabilities for late-stage clinical and commercial production.
October 2025 FUJIFILM Diosynth Biotechnologies expanded its CDMO capabilities through new biomanufacturing facilities dedicated to biologics, cell culture, and recombinant protein production.
June 2025 Thermo Fisher Scientific expanded its biologics manufacturing services by introducing enhanced end-to-end CDMO solutions supporting biologic drug development and commercial manufacturing.